Clinical Trial Update: Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 trial from the University of Copenhagen evaluating phosphodiesterase inhibitors for cognitive deficits in schizophrenia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Phosphodiesterase inhibitors (phosphodiesterase inhibitor)

Snippet

Sponsor: University of Copenhagen | Conditions: Schizophrenia, Cognitive Deficits | EARLY_Phase 1 | Status: TERMINATED